Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily antibiotic keep kids with leukemia safer from infection?

NCT ID NCT04678869

Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving children with acute lymphoblastic leukemia a daily antibiotic called ciprofloxacin can reduce bacterial infections during the first month of chemotherapy. About 313 children in the UK are taking part. The goal is to see if this approach works better than standard care and to check for antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

313 people

The number who actually took part.

Started

Jun 2022

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Paediatric patients (1-17 years inclusive) with de-novo Acute Lymphoblastic Leukaemia treated on ALLTogether-1 in the UK in the first 5 days of therapy, up to 14 days is acceptable. * Written informed consent Exclusion Criteria: * Non-participants of the ALLTogether-1 trial * Patients with Down syndrome who already receive ciprofloxacin prophylaxis * Chronic active arthritis * Other contraindication to fluoroquinolones

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukaemia - category are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia bacterial infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukaemia - category

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • Alder Hey Children's Hospital

    Liverpool, United Kingdom

  • Bristol Royal Hospital for Children

    Bristol, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • John Radcliffe Hospital

    Oxford, United Kingdom

  • Leeds General Infirmary

    Leeds, United Kingdom

  • Leicester Royal Infirmary

    Leicester, United Kingdom

  • Nottingham Children's Hospital

    Nottingham, United Kingdom

  • Royal Aberdeen Children's Hospital

    Aberdeen, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Royal Victoria Infirmary

    Newcastle, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

  • Univeristy College Hospital London

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.